Clinical Trial Update: Dose Optimization Study of Idelalisib in Follicular Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 dose optimization study of idelalisib in follicular lymphoma has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Idelalisib (idelalisib)

Snippet

Sponsor: Gilead Sciences | Conditions: Follicular Lymphoma | Phase 3 | Status: TERMINATED | Results posted: 2023-08-14